The most common grade @ or @ adverse events were low neutrophil count ( @ -LSB- @ % -RSB- preoperatively in the chemotherapy alone group vs six -LSB- @ % -RSB- in the chemotherapy plus cetuximab group ; four -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- postoperatively ) , embolic events ( six -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- preoperatively ; two -LSB- @ % -RSB- vs three -LSB- @ % -RSB- postoperatively ) , peripheral neuropathy ( six -LSB- @ % -RSB- vs one -LSB- @ % -RSB- preoperatively ; two -LSB- @ % -RSB- vs four -LSB- @ % -RSB- postoperatively ) , nausea or vomiting ( four -LSB- @ % -RSB- vs six -LSB- @ % -RSB- preoperatively ; four -LSB- @ % -RSB- vs two -LSB- @ % -RSB- postoperatively ) , and skin rash ( two -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- preoperatively ; @ vs eight -LSB- @ % -RSB- postoperatively ) .